Survival of cancer patients treated with monoclonal antibodies versus conventionalprocedure at the Unidad Oncológica Surcolombiana 2010 2015

Abstract

Introduction: the increase in cancer cases has generated a high social impact that has led to the development of different treatments. Objective: this study aims to understand the survival of cancer patients with monoclonal antibodies versus conventional treatment in the Unidad Oncológica Surcolombiana, from January 2010 to December 2015. Method: the study type is a retrospective analytical study of cases and controls. The Kaplan Meier survival function was used for the investigation with a total sample of 2098 participants who fulfilled the inclusion criteria. Results: the female population was the largest cancer registry, with breast cancer being the most predominant. Increased survival was found in patients with prostate cancer in 5 years. At the 72nd month, 65% of the patients with monoclonal antibodies were alive compared to 50% without this treatment. In lung cancer, survival at 24 months with monoclonal therapy indicated 62%, compared to 11% with therapies without
MAB. For stomach cancer, there was evidence of an 80% increase in survival at 40 months of treatment. Overall, during the monitored period, 92 of the 258 patients treated with monoclonal antibodies died, while 547 of the 1840 patients who were given a different therapy died. Conclusions: with respect to the control group, the study made it possible to recognize the advantages of monoclonal antibody therapy for the survival of cancer patients with respect to other conventional treatments.